IRVINE, Calif., Feb. 27, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, reported today that total revenues for the fourth quarter and full-year 2012, increased to $1.5 million and $5.4 million, respectively, up 18% and 15% from the fourth quarter and full-year 2011. Revenues from the Company's core prenatal testing markets in the fourth quarter grew by 161% over the corresponding period in 2011 and grew by more than 101% for full-year 2012 over the comparable prior year. On a sequential basis, prenatal testing revenues in the 2012 fourth quarter grew by 76% over the 2012 third quarter.
CombiMatrix Corporation Reports Results For 2012 Fourth Quarter
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts